Homologous recombination repair gene alterations in prostate cancer: expert recommendations for genetic and biomarker testing
Year: 2026
Type: article
Abstract: PURPOSE OF REVIEW: Homologous recombination repair (HRR) gene alterations are associated with genomic instability and more aggressive prostate cancer (PCa) leading to worse clinical outcomes. poly(ADP-ribose) polymerase inhibitors have demonstrated significant clinical benefit in patients with HRR-altered tumors, and international guidelines now recommend HRR testing. Nevertheless, real-world adoption of this testing remains inconsistent across healthcare systems. To address this gap, we developed expert-driven, practical recommendations for integrating HRR testing into clinical practice for patients with PCa. RECENT FINDINGS: The panel developed consensus recommendations addressing the optimal timing of HRR testing, patient selection criteria, appropriate use of genetic and biomarker testing platforms, and interpretation of test results. Hypothetical case studies illustrated application in clinical settings. These recommendations are evidence-based but reflect expert opinion and should be tailored to local circumstances. No statistical analyses were performed; generalizability may be influenced by differences between healthcare systems. SUMMARY: These expert consensus recommendations provide practical guidance on facilitating the broader and more consistent implementation of HRR testing in men with PCa. Wider adoption of such testing may enable more personalized treatment approaches and lead to improved patient outcomes.
Source: Current Opinion in Urology
Institutions: Al-Ahliyya Amman University, Charles University, Weill Cornell Medicine, Medical University of Vienna, The University of Texas Southwestern Medical Center, University of Michigan, University of British Columbia, Vancouver Prostate Centre, Radboud University Medical Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Pfizer (United States), Jena University Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Pfizer
OpenAlex ID: W7236332227
